A number of pyrimidine bridged combretastatin derivatives were designed, synthesized and evaluated for anticancer activities against breast cancer (MCF-7) and lung cancer (A549) cell lines using MTT assays. Most of the synthesized compounds displayed good anticancer activity with IC₅₀ values in low micro-molar range. Compounds 4a and 4p were found most potent in the series with IC₅₀ values of 4.67 µM & 3.38 µM and 4.63 µM & 3.71 µM against MCF7 and A549 cancer cell lines, respectively. Biological evaluation of these compounds showed that selective cancer cell toxicity (in vitro using human lung and breast cancer cell lines) might be due to the inhibition of antioxidant enzymes instigating elevated ROS levels which triggers intrinsic apoptotic pathways. These compounds were found nontoxic to the normal human primary cells. Compound 4a, was found to be competitive inhibitor of colchicine and in the tubulin binding assay it showed tubulin polymerization inhibition potential comparable to colchicine. The molecular modeling studies also showed that the synthesized compounds fit well in the colchicine-binding pocket.

使用MTT分析法设计，合成和评估了许多嘧啶桥联的康他汀衍生物，并评估了它们对乳腺癌（MCF-7）和肺癌（A549）细胞系的抗癌活性。大多数合成的化合物显示出良好的抗癌活性，其IC ₅₀值在低微摩尔范围内。化合物4a和4p在该系列中最有效，对MCF7和A549癌细胞系的IC ₅₀值分别为4.67 µM和3.38 µM和4.63 µM和3.71 µM。这些化合物的生物学评估表明，选择性癌细胞毒性（体外使用人肺癌和乳腺癌细胞系）可能是由于抗氧化剂酶的抑制导致ROS水平升高，从而触发了内在的凋亡途径。发现这些化合物对正常人原代细胞无毒。发现化合物4a是秋水仙碱的竞争性抑制剂，并且在微管蛋白结合测定中显示出与秋水仙碱相当的微管蛋白聚合抑制潜能。分子模型研究还表明，合成的化合物很好地适合秋水仙碱结合袋。